105 Participants Needed

JANX007 for Prostate Cancer

Recruiting at 16 trial locations
JT
Overseen ByJanux Therapeutics
Age: 18+
Sex: Male
Trial Phase: Phase 1
Sponsor: Janux Therapeutics
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

What is the purpose of this trial?

This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 administered as a single agent in adults with metastatic castration-resistant prostate cancer (mCRPC).

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the drug JANX007 for prostate cancer?

Research on similar treatments like 177Lu-PSMA-617 shows that it can reduce tumor volume and improve survival in prostate cancer patients, especially when the cancer cells have high PSMA levels. This suggests that JANX007, which targets PSMA, might also be effective in treating prostate cancer.12345

What safety data exists for PSMA-targeted therapies like JANX007 in humans?

PSMA-targeted therapies, such as 177Lu-PSMA-617, have been shown to be generally safe and well-tolerated in humans, with common side effects including dry mouth, fatigue, nausea, and diarrhea, which are manageable with standard medical care. Serious side effects were rare and included conditions like anemia and kidney injury, but these were not definitively linked to the treatment.678910

What makes the drug JANX007 unique for treating prostate cancer?

JANX007, also known as PSMA-TRACTr, is unique because it targets the prostate-specific membrane antigen (PSMA) on cancer cells, potentially offering a more precise treatment for prostate cancer compared to traditional therapies. This targeted approach may help reduce damage to healthy cells and improve treatment outcomes.611121314

Research Team

JT

Janux Therapeutics, MD

Principal Investigator

Janux Therapeutics

Eligibility Criteria

This trial is for adult men with metastatic castration-resistant prostate cancer who have already tried at least one novel anti-androgen therapy and a taxane regimen, or cannot take taxane due to medical reasons. They must have a PSMA expressing tumor, no significant heart disease, no organ transplants, and no active serious infections.

Inclusion Criteria

My organs are working well.
My prostate cancer was confirmed by a lab test.
I am a man aged 18 or older.
See 1 more

Exclusion Criteria

I do not have any serious infections.
I don't have any health issues that could affect the study's safety or results.
I have had a solid organ transplant.
See 2 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Dose Escalation

IV dosing during 21- or 28-day cycles to determine the maximum tolerable dose

Varies per cohort

Expansion

IV dosing during 21- or 28-day cycles at preliminary recommended phase 2 dose (RP2D)

Varies per cohort

Backfill Expansion

IV dosing during 21- or 28-day cycles at levels previously declared tolerable

Varies per cohort

Follow-up

Participants are monitored for safety and effectiveness after treatment

Up to 3 years

Treatment Details

Interventions

  • JANX007
Trial OverviewThe study tests JANX007's safety, how well it's tolerated by the body (tolerability), its behavior in the body (pharmacokinetics), its effect on the body (pharmacodynamics), and initial effectiveness in treating advanced prostate cancer that resists standard treatments.
Participant Groups
3Treatment groups
Experimental Treatment
Group I: ExpansionExperimental Treatment1 Intervention
IV dosing during 21- or 28-day cycles. Subjects will be dosed at preliminary recommended phase 2 dose (RP2D).
Group II: Dose EscalationExperimental Treatment1 Intervention
IV dosing during 21- or 28-day cycles. Dosage per cohort will increase to determine the maximum tolerable dose.
Group III: Backfill ExpansionExperimental Treatment1 Intervention
IV dosing during 21- or 28-day cycles. Subjects will be dosed at levels previously declared tolerable.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Janux Therapeutics

Lead Sponsor

Trials
2
Recruited
240+

Findings from Research

In a study of 86 patients with castration-resistant prostate cancer (CRPC) treated with [177Lu]-Lutetium-PSMA, the median overall survival was 15 months, indicating that this treatment can be effective for some patients.
Key predictors for better survival included a pre-treatment hemoglobin level of ≥10 g/dL and lower PSA values at the start of treatment, suggesting that these factors could help identify patients who are more likely to benefit from Lu-PSMA therapy.
Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre.Thaiss, W., Zengerling, F., Friedrich, J., et al.[2023]
In a study involving 270 patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Lutetium-177 (177Lu-PSMA), nomograms were developed to predict overall survival and PSA-progression-free survival based on various clinical and imaging factors, achieving a C-index of 0.71 for overall survival.
The nomograms effectively stratified patients into low-risk and high-risk groups, with low-risk patients showing significantly longer overall survival (24.9 months) compared to high-risk patients (7.4 months), indicating their potential utility in clinical decision-making and trial design.
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study.Gafita, A., Calais, J., Grogan, TR., et al.[2021]
In a study of 33 patients with metastatic castration-resistant prostate cancer undergoing [177Lu]-PSMA-617 therapy, baseline tumor volume (PSMA-TV) was found to be a significant predictor of overall survival (OS), indicating that larger tumor volumes at the start of treatment correlate with poorer outcomes.
Reduction in PSMA-TV after two therapy cycles did not generally predict better OS for the entire cohort; however, in patients with higher PSMA expression, a reduction in PSMA-TV was associated with improved survival, suggesting that PSMA expression levels may influence the effectiveness of tumor volume assessments.
Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy.Seifert, R., Kessel, K., Schlack, K., et al.[2022]

References

Personalized [177Lu]Lutetium-PSMA Therapy for Patients with Pre-Treated Castration-Resistant Prostate Cancer: A Single Institution Experience from a Comprehensive Cancer Centre. [2023]
Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. [2021]
Total tumor volume reduction and low PSMA expression in patients receiving Lu-PSMA therapy. [2022]
Can PSMA-based tumor burden predict response to docetaxel treatment in metastatic castration-resistant prostate cancer? [2021]
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN). [2023]
Safety of PSMA-Targeted Molecular Radioligand Therapy with 177Lu-PSMA-617: Results from the Prospective Multicenter Phase 2 Trial RESIST-PC (NCT03042312). [2023]
Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225. [2023]
Prostate-Specific Membrane Antigen Targeted Therapy of Prostate Cancer Using a DUPA-Paclitaxel Conjugate. [2019]
Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer. [2021]
10.United Statespubmed.ncbi.nlm.nih.gov
An Improved 211At-Labeled Agent for PSMA-Targeted α-Therapy. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I/II Trial. [2022]
12.United Statespubmed.ncbi.nlm.nih.gov
FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. [2023]
LUNAR: a randomized Phase 2 study of 177 Lutetium-PSMA Neoadjuvant to Ablative Radiotherapy for Oligorecurrent Prostate Cancer (clinical trial protocol). [2023]
14.United Statespubmed.ncbi.nlm.nih.gov
Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. [2022]